Nathan Merrill
YOU?
Author Swipe
View article: EXTH-15. Combinatorial targeting of avapritinib-driven MAPK activation in pediatric high-grade glioma
EXTH-15. Combinatorial targeting of avapritinib-driven MAPK activation in pediatric high-grade glioma Open
PDGFRA is a frequently altered gene in pHGG, driving aggressive behavior and worse prognoses. Avapritinib, a CNS-penetrant inhibitor of mutated PDGFRα and KIT kinases, has shown promise in vitro, in vivo, and in pHGG patients. Single-agent…
View article: TMOD-21. Precision Oncology for High-Grade Gliomas: A Tumor Organoid Platform for Rapid, Patient-Specific Drug Screening
TMOD-21. Precision Oncology for High-Grade Gliomas: A Tumor Organoid Platform for Rapid, Patient-Specific Drug Screening Open
INTRODUCTION High-grade gliomas (HGGs) are aggressive, treatment-resistant brain tumors marked by extensive intratumoral heterogeneity, complicating formulation of effective adjuvant therapy. Standard of care treatment is unimodal and fail…
View article: TMOD-31. Patient-derived “tumor-oids” recapitulate the tumor microenvironment and allow for pre-clinical drug screening across the entire spectrum of pediatric brain tumors
TMOD-31. Patient-derived “tumor-oids” recapitulate the tumor microenvironment and allow for pre-clinical drug screening across the entire spectrum of pediatric brain tumors Open
Traditional cell culture models are often infeasible and fail to adequately capture the tumor microenvironment of pediatric brain tumors. To address this gap, we developed a live bio-bank of patient-derived tumor-oids (PDTs) without single…
View article: Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection Open
High-grade gliomas (HGGs) are aggressive brain tumors with limited treatment options and poor survival outcomes. Variants including isocitrate dehydrogenase (IDH)-wildtype, IDH-mutant, and histone 3 lysine to methionine substitution (H3K27…
View article: TRLS-04 ENHANCING PRECISION MEDICINE THROUGH FUNCTIONAL DRUG TESTING FOR PATIENTS WITH BREAST CANCER BRAIN METASTASES.
TRLS-04 ENHANCING PRECISION MEDICINE THROUGH FUNCTIONAL DRUG TESTING FOR PATIENTS WITH BREAST CANCER BRAIN METASTASES. Open
Breast cancer brain metastases (BCBrMet) increase mortality among breast cancer patients. Our previous research confirmed the feasibility of real-time drug testing to guide personalized therapy for BCBrMet (Morikawa JCO Glo Onc suppl 2023)…
View article: 8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers Open
View article: Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion
Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion Open
Fatty acid synthesis (FAS) has been shown to play a key role in the survival of brain-metastatic (BM) breast cancer. We demonstrate that the fatty acid synthase inhibitor TVB-2640 synergizes with the topoisomerase inhibitor SN-38 in triple…
View article: Antigen-Independent Single-Cell Circulating Tumor Cell Detection Using Deep-Learning-Assisted Biolasers
Antigen-Independent Single-Cell Circulating Tumor Cell Detection Using Deep-Learning-Assisted Biolasers Open
View article: Precision Medicine-Based Platform to Guide the Treatment of EML4-ALK Lung Cancers and Other Non-Small Cell Lung Cancers
Precision Medicine-Based Platform to Guide the Treatment of EML4-ALK Lung Cancers and Other Non-Small Cell Lung Cancers Open
View article: EP12.02-03 Judith Tam ALK Lung Cancer Research Initiative
EP12.02-03 Judith Tam ALK Lung Cancer Research Initiative Open
View article: 159P Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
159P Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC Open
Lung cancer (LC) remains the top cause of cancer-associated mortality worldwide, with a 10-year overall survival rate of only 5%. While most LCs are smoking related, 25% of non-small cell LC (NSCLC) are diagnosed in patients with little or…
View article: 136P Molecular correlates of drug response to guide therapy in TNBC
136P Molecular correlates of drug response to guide therapy in TNBC Open
TNBC is more likely to metastasize within 3-5 years than other forms of breast cancer and has a median survival of 17.6-21.3 months after metastasis. Recent advances are promising, but trial results of immunotherapy-chemo combinations have…
View article: Blood–Brain Barrier Remodeling in an Organ‐on‐a‐Chip Device Showing Dkk1 to be a Regulator of Early Metastasis
Blood–Brain Barrier Remodeling in an Organ‐on‐a‐Chip Device Showing Dkk1 to be a Regulator of Early Metastasis Open
Adv. NanoBiomed Res. 2023, 3, 2200036 DOI: 10.1002/anbr.202200036 In the initially published version of this article, the last name of the author Nathan M. Merrill was misspelled as Nathan M. Merill.
View article: Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other non-small cell lung cancers.
Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other non-small cell lung cancers. Open
146 Background: Lung cancer remains the number one cause of cancer-associated mortality worldwide, with a 10-year survival rate of only 5%. While most lung cancers are smoking related, 25% of non-small cell lung cancer (NSCLC) are diagnose…
View article: Personalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing.
Personalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing. Open
11 Background: Therapeutic development for BrMets remains a critical need. Our previous work on functional precision medicine using patient-derived xenografts (PDXs) from BrMets suggested that drug sensitivity testing may help prioritize d…
View article: FIGURE 1 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
FIGURE 1 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
Volcano plot of differentially expressed genes comparing the paired brain metastases and primary breast tumor (Group A). The downregulated and the upregulated genes in the brain metastases samples compared with the matched primary breast t…
View article: Supplementary Data S3a and S3b from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Supplementary Data S3a and S3b from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
Genomic comparison across the different metastatic sites compared to the matched primary. A. Genomic alterations across metastatic sites compared to matched primary B. Copy number variations across metastatic sites compared to matched prim…
View article: Data from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Data from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
The development of novel therapies for brain metastases is an unmet need. Brain metastases may have unique molecular features that could be explored as therapeutic targets. A better understanding of the drug sensitivity of live cells coupl…
View article: TABLE 1 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
TABLE 1 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
GSEA using the Hallmark gene sets comparing the paired brain metastases and primary breast tumors. Gene sets with FDR < 0.05
View article: Supplementary Data S4 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Supplementary Data S4 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
Ipathway analysis table
View article: Supplementary Data S3a and S3b from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Supplementary Data S3a and S3b from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
Genomic comparison across the different metastatic sites compared to the matched primary. A. Genomic alterations across metastatic sites compared to matched primary B. Copy number variations across metastatic sites compared to matched prim…
View article: TABLE 3 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
TABLE 3 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
Molecular targeted drugs with very high DSS3 values
View article: Supplementary Data S7 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Supplementary Data S7 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
PDX molecular profiling
View article: FIGURE 1 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
FIGURE 1 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
Volcano plot of differentially expressed genes comparing the paired brain metastases and primary breast tumor (Group A). The downregulated and the upregulated genes in the brain metastases samples compared with the matched primary breast t…
View article: TABLE 2 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
TABLE 2 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
Drug responses (DSS3 values) matched to potentially actionable genomic alterations in BCBM PDX models
View article: FIGURE 2 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
FIGURE 2 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
Heat map from the Hallmark gene sets GSVA comparing the paired brain metastases and primary breast tumor (Group A). HR, hormone receptor; HER2, human epidermal growth factor 2.
View article: Supplementary Data S5 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Supplementary Data S5 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
GSEA analysis using the oncogenic, KEGG, and GOBP gene sets.
View article: Supplementary Data S5 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Supplementary Data S5 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
GSEA analysis using the oncogenic, KEGG, and GOBP gene sets.
View article: Supplementary Data S1a and S1b from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Supplementary Data S1a and S1b from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
S1a. Breast cancer brain metastases cohort (Group A) selection S1b. Clinical characteristics of breast cancer brain metastases cohort (Group A)
View article: Supplementary Data S7 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Supplementary Data S7 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment Open
PDX molecular profiling